Novavax Surging In Pre-Market On Government Vaccine Contract

Rocket China

Novavax was up 33% in pre-market trading on its new vaccine development contract with the the U.S. government.

The contract is for flu other pandemic vaccines, and could have its lifespan increased to 24 months. That would add an additional $82 million to the deal, making it worth $179 million to the company.

The stock closed in the previous session at $2.60.

Take a look at what analysts are telling their clients about stocks this morning >

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at